Clinical Trials Directory

Trials / Completed

CompletedNCT00566423

Biomarkers in the Diagnosis and Assessment of Pulmonary Arterial Hypertension (PAH)

Biomarkers in the Diagnosis and Assessment of PAH

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
75 (actual)
Sponsor
Northwell Health · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

The investigators hypothesize that baseline plasma brain natriuretic peptide (BNP) and migration inhibitory factor (MIF) levels are surrogate markers of clinical severity of PAH and that changes in plasma brain natriuretic peptide (BNP) and MIF levels pre and post exercise.

Detailed description

As above

Conditions

Interventions

TypeNameDescription
OTHERBlood drawVenous and Arterial Blood draw samples; 6 Minute Walk test

Timeline

Start date
2007-05-01
Primary completion
2008-05-01
Completion
2010-06-01
First posted
2007-12-03
Last updated
2011-06-23

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00566423. Inclusion in this directory is not an endorsement.

Biomarkers in the Diagnosis and Assessment of Pulmonary Arterial Hypertension (PAH) (NCT00566423) · Clinical Trials Directory